GlassScriptPhysician profile
Daniel T Torzala
NPI 1437127990
$11,407.34
in general payments reported to CMS, 2019-2025
69 companies · $2,795 in 2025
The $2,795 reported for 2025 was more than what 78% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,231 · 2020: $905 · 2021: $1,664 · 2022: $1,534 · 2023: $1,484 · 2024: $1,795 · 2025: $2,795.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,074.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,073.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,035.38 | 2021-2025 | Ubrelvy, Qulipta |
| Ucb, INC. | $1,209.75 | 2019-2025 | Briviact, Rystiggo, Nayzilam |
| Jazz Pharmaceuticals INC. | $719.38 | 2019-2025 | |
| Biogen, INC. | $634.20 | 2019-2025 | Vumerity, Tysabri, Spinraza |
| Novartis Pharmaceuticals Corporation | $504.38 | 2019-2025 | |
| Pfizer INC. | $467.58 | 2023-2025 | |
| Alexion Pharmaceuticals, INC. | $381.06 | 2021-2025 | Ultomiris |
| Sk Life Science, INC. | $342.79 | 2020-2025 | |
| Lilly USA, LLC | $336.19 | 2019-2025 | Emgality, Kisunla, Amyvid |
| Teva Pharmaceuticals USA, INC. | $319.18 | 2019-2025 | Austedo Xr, Ajovy |
| Amgen INC. | $262.36 | 2019-2022 | |
| Genzyme Corporation | $233.56 | 2021-2025 | |
| Genentech USA, INC. | $202.32 | 2025 | Ocrevus Zunovo, Ocrevus |
| Neurelis, INC. | $198.82 | 2020-2025 | Valtoco |
| Lundbeck LLC | $197.33 | 2021-2025 | Vyepti, Rexulti |
Show all 69 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Torzala listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.